Cosmo Pharmaceuticals N.V
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesa… Read more
Cosmo Pharmaceuticals N.V (CMOPF) - Total Assets
Latest total assets as of June 2025: $610.33 Million USD
Based on the latest financial reports, Cosmo Pharmaceuticals N.V (CMOPF) holds total assets worth $610.33 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cosmo Pharmaceuticals N.V - Total Assets Trend (2004–2024)
This chart illustrates how Cosmo Pharmaceuticals N.V’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cosmo Pharmaceuticals N.V - Asset Composition Analysis
Current Asset Composition (December 2024)
Cosmo Pharmaceuticals N.V's total assets of $610.33 Million consist of 31.3% current assets and 68.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.9% |
| Accounts Receivable | $18.94 Million | 2.9% |
| Inventory | $13.51 Million | 2.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $331.93 Million | 51.3% |
| Goodwill | $24.00 Million | 3.7% |
Asset Composition Trend (2004–2024)
This chart illustrates how Cosmo Pharmaceuticals N.V's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cosmo Pharmaceuticals N.V's current assets represent 31.3% of total assets in 2024, an increase from 17.7% in 2004.
- Cash Position: Cash and equivalents constituted 6.9% of total assets in 2024, up from 1.2% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 54.0% of total assets, an increase from 4.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 51.3% of total assets.
Cosmo Pharmaceuticals N.V Competitors by Total Assets
Key competitors of Cosmo Pharmaceuticals N.V based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.55 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.07 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367
|
China | CN¥1.52 Billion |
Cosmo Pharmaceuticals N.V - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Cosmo Pharmaceuticals N.V generates 0.41x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Cosmo Pharmaceuticals N.V generates $ 20.60 in net profit.
Cosmo Pharmaceuticals N.V - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.84 | 4.85 | 16.96 |
| Quick Ratio | 3.59 | 4.48 | 16.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $138.51 Million | $ 145.72 Million | $ 274.70 Million |
Cosmo Pharmaceuticals N.V - Advanced Valuation Insights
This section examines the relationship between Cosmo Pharmaceuticals N.V's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.87 |
| Latest Market Cap to Assets Ratio | 0.82 |
| Asset Growth Rate (YoY) | 16.8% |
| Total Assets | $646.77 Million |
| Market Capitalization | $529.97 Million USD |
Valuation Analysis
Near Book Valuation: The market values Cosmo Pharmaceuticals N.V's assets close to their book value ( 0.82x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Cosmo Pharmaceuticals N.V's assets grew by 16.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cosmo Pharmaceuticals N.V (2004–2024)
The table below shows the annual total assets of Cosmo Pharmaceuticals N.V from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $646.77 Million | +16.75% |
| 2023-12-31 | $553.98 Million | -27.07% |
| 2022-12-31 | $759.59 Million | -5.71% |
| 2021-12-31 | $805.56 Million | +35.12% |
| 2020-12-31 | $596.16 Million | +1.88% |
| 2019-12-31 | $585.16 Million | -6.48% |
| 2018-12-31 | $625.69 Million | +25.65% |
| 2017-12-31 | $497.97 Million | +12.29% |
| 2016-12-31 | $443.47 Million | +1.26% |
| 2015-12-31 | $437.94 Million | +94.11% |
| 2014-12-31 | $225.62 Million | -7.15% |
| 2013-12-31 | $243.00 Million | +60.03% |
| 2012-12-31 | $151.84 Million | +94.58% |
| 2011-12-31 | $78.04 Million | -15.01% |
| 2010-12-31 | $91.83 Million | +28.49% |
| 2009-12-31 | $71.46 Million | +23.72% |
| 2008-12-31 | $57.77 Million | +22.31% |
| 2007-12-31 | $47.23 Million | +100.03% |
| 2006-12-31 | $23.61 Million | -16.31% |
| 2005-12-31 | $28.21 Million | +20.24% |
| 2004-12-31 | $23.46 Million | -- |